XML 75 R27.htm IDEA: XBRL DOCUMENT v3.25.1
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenues from Collaboration and Licensing Agreements
Revenues from collaboration and license agreements as a percentage of total revenues were as follows:
Year Ended December 31,
20242023
Genentech, Inc.87 %— %
Astellas Gene Therapies, Inc.11 %— %
Other licensing agreements2 %11 %
Biogen MA, Inc.— %77 %
Kite Pharma, Inc.— %12 %
Schedule of Percentage of Accounts Receivable by Collaboration Partners As of December 31, 2024 and 2023, the percentage of accounts receivable by collaboration partners who individually accounted for 10% or more of accounts receivable were as follows:
As of December 31,
20242023
Sigma-Aldrich Corporation
70 %78 %
Ligand Pharmaceuticals Inc.
20 %5 %
Kite Pharma, Inc.— %18 %
Schedule of Cash and Cash Equivalents
A reconciliation of cash, cash equivalents and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):
As of December 31,
20242023
Cash and cash equivalents$41,918 $45,204 
Non-current restricted cash1,500 1,500 
Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows$43,418 $46,704 
Schedule of Restricted Cash
A reconciliation of cash, cash equivalents and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):
As of December 31,
20242023
Cash and cash equivalents$41,918 $45,204 
Non-current restricted cash1,500 1,500 
Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows$43,418 $46,704